Anupam Rasayan Board Approves FY26 Results, Recommends Dividend, Acquires Bliss GVS Pharma Stake
Anupam Rasayan's Board approved FY26 results and recommended a final dividend of ₹1.5 per share. The company will acquire up to 74.20% of Bliss GVS Pharma and raise ₹160 crore via NCDs. Mr. Vishal Thakkar resigned as Deputy CFO.
The acquisition of a significant stake in another listed company and the fundraising through NCDs are material events that are likely to have a substantial impact on the company's financial structure and business operations.
The company reported its financial results, recommended a dividend, and announced a strategic acquisition and debt fundraising, all of which are generally positive developments.
Anupam Rasayan India Limited announced the outcome of its Board Meeting held on May 23, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The statutory auditors, Natvarlal Vepari & Co., issued an unmodified opinion on these results.
The Board recommended a Final Dividend of ₹1.5 per Equity Share (15%) for the financial year 2025-26, subject to shareholder approval at the upcoming 23rd Annual General Meeting. Additionally, the company approved the acquisition of up to 74.20% equity shares and control of Bliss GVS Pharma Limited, a publicly listed company.
Further, the company resolved to raise funds by issuing 16,000 Secured, Rated, Unlisted, Redeemable, Non-Convertible Debentures (NCDs) with a face value of ₹1,00,000 each, aggregating up to ₹160 crore, on a private placement basis.
The Board also approved the re-appointment of M/s. KB. Daliya & Associates as Internal Auditors and M/s. Bhanwarlal Gurjar & Co. as Cost Auditors for the financial year 2026-27. The company accepted the resignation of Mr. Vishal Thakkar from the post of Deputy Chief Financial Officer and Key Managerial Personnel with immediate effect.
The Board meeting commenced at 12:45 p.m. IST and concluded at 04:55 p.m. IST.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.